Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature
- PMID: 32557623
- PMCID: PMC7300950
- DOI: 10.1111/bjh.16896
Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature
Abstract
SARS-CoV-2 infection can cause severe pneumonia (COVID-19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SARS-CoV-2 viraemia with fatal outcome in patients after rituximab therapy.
Keywords: COVID-19; SARS-CoV-2; pneumonia; rituximab; viraemia.
© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Figures
Comment in
-
Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery.Br J Haematol. 2020 Aug;190(3):e154-e156. doi: 10.1111/bjh.16981. Epub 2020 Jul 16. Br J Haematol. 2020. PMID: 32593180 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
